Seres Therapeutics, Inc.
MCRB
$6.33
$0.050.80%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -14.03% | -25.02% | -18.88% | -7.45% | -21.27% |
| Gross Profit | 16.36% | 27.70% | 21.01% | 7.45% | 21.27% |
| SG&A Expenses | -32.12% | -39.50% | -25.44% | -21.52% | -20.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.92% | -31.28% | -21.74% | -13.82% | -20.91% |
| Operating Income | 23.24% | 32.80% | 22.94% | 13.82% | 20.91% |
| Income Before Tax | -160.93% | 1.93% | 116.08% | 24.21% | 199.33% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -160.93% | 1.93% | 116.08% | 24.21% | 199.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -160.93% | 1.93% | -90.76% | 39.60% | 181.43% |
| EBIT | 23.24% | 32.80% | 22.94% | 13.82% | 20.91% |
| EBITDA | 23.07% | 33.61% | 22.81% | 13.22% | 20.44% |
| EPS Basic | -155.34% | 8.99% | -91.95% | 47.66% | 168.35% |
| Normalized Basic EPS | 7.25% | -841.07% | 67.53% | 33.72% | 50.26% |
| EPS Diluted | -155.47% | 9.37% | -91.94% | 47.69% | 168.26% |
| Normalized Diluted EPS | 7.12% | -841.07% | 67.58% | 33.72% | 50.33% |
| Average Basic Shares Outstanding | 10.10% | 7.75% | 14.76% | 15.42% | 19.14% |
| Average Diluted Shares Outstanding | 9.96% | 7.75% | 14.93% | 15.42% | 19.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |